A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and SA
Research payments
$1,048,670
Through program year 2021, $1,048,670 in research payments was reported against A Phase 2 Open-Label, Single-Arm Study to Evaluate the Efficacy and SA, across 113 payments, paid by GlaxoSmithKline, LLC..
- Paid by
- GlaxoSmithKline, LLC.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2021 | Research | $52,342 | 12 |
| 2020 | Research | $996,329 | 101 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Adam Elnaggar Columbus, OH Named on 13 payments
- Emily Prendergast Los Angeles, CA Named on 13 payments
- Corrine Zarwan Burlington, MA Named on 9 payments
- Hye Sook Chon Tampa, FL Named on 8 payments
- Elizabeth Lokich Providence, RI Named on 7 payments
- Robert Holloway Crestview, FL Named on 6 payments
- Marilyn Huang Miami, FL Named on 5 payments
- Linda Duska Charlottesville, VA Named on 4 payments
- Roisin O'Cearbhaill New York, NY Named on 4 payments
- Steven Waggoner Cleveland, OH Named on 4 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.